Search Results 251-260 of 17392 for Interferon
Patients previously treated with MDM2 antagonist therapies or patients receiving interferon-alpha, anagrelide, or ruxolitinib within 28 days or 5 half-lives ...
Patients must not have received any prior or concurrent systemic chemotherapy or immunotherapy (prior intravesical chemotherapy and interferon is permitted).
Participation eligibility · Patients with active tuberculosis should be excluded; · Patients will be screened with Interferon Gamma Release Assay (IGRA) such as ...
Pretreatment with interferon as last treatment prior to start of study treatment. Prior treatment for study indication with: Antibodies or immunotherapy ...
Preemployment screening for tuberculosis in a large health care setting: comparison of the tuberculin skin test and a whole-blood interferon-gamma release assay ...
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 6 weeks or 5 half-lives of the drug, whichever is ...
JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
... interferon or other anti-HCV therapy will be excluded from study; Active autoimmune disease or history of autoimmune disease that might recur, which may ...
Multiple sclerosis often is initially treated with interferon beta medications that work by reducing inflammation. These medications don't help patients ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.